The Risk of Tier 2 Suppliers in the Medical Device Supply Chain

The Assumption That’s Leaving OEMs Exposed

For the past several years, the dominant response to tariff pressure in medical device manufacturing has been to move closer to home. And for many OEMs, choosing a U.S.-based contract manufacturer has genuinely reduced exposure at the finished-goods level. But the logic breaks down when you look past the CM itself and ask where they source components, materials, and specialty inputs.

There’s an assumption that domestic manufacturing relationships create a domestic supply chain, but most contract manufacturers operate within multi-tier sourcing networks that extend across multiple countries and continents. The CM assembles domestically, but the raw materials, subcomponents, and precision inputs that make assembly possible may travel through supply nodes in China, Taiwan, Malaysia, or elsewhere.

When tariffs target those upstream materials, the cost hits your CM’s inputs, and eventually, it hits you. The geography of final assembly and the geography of medical device supply chain risk are not the same thing.

Understanding the Supplier Tier Structure

To understand where risk concentrates, it helps to be precise about what the tier structure actually looks like in practice. Most medical device supply chain discussions collapse the complexity into a single “supplier” category, but the reality is a layered network where each level carries its own risk profile, its own tariff exposure, and its own degree of visibility.

Tier 1: Your Contract Manufacturer

Your Tier 1 relationship is the one you can see. This is your medical device contract manufacturer. You know their facility, their quality certifications, their lead times, and their production capacity. This is also where most tariff risk conversations stop, which is precisely the problem. Visibility at Tier 1 is relatively straightforward. It’s everything downstream of it that creates the blind spot.

Tier 2: Your CM’s Component Suppliers

Tier 2 suppliers are the companies your CM sources from directly. Your CM has relationships with these vendors, but you typically do not. There are no direct contracts between an OEM and its Tier 2 supplier base, which means there’s no formal mechanism for the OEM to request sourcing data or conduct audits. A medical device tariff that hits a Tier 2 component supplier flows upstream to your CM as a cost increase, and eventually is passed along to you.

Tier 3: Raw Materials and Specialty Inputs

Tier 3 is where raw materials originate. It’s the specialty plastics, metals, electronic substrates, and chemical compounds that Tier 2 component manufacturers rely on to produce what they sell to your CM. This layer is almost completely opaque to OEMs, and yet it’s one of the most tariff-sensitive points in the entire chain. Section 301 duties on Chinese imports, for example, apply to the materials that flow through this tier into medical device production, meaning that tariff exposure can enter your program at the raw-material level.

Where the Tariff Risk Actually Lives

The practical consequence of this structure is that medical device supply chain tariff risk is concentrated precisely where OEM visibility is weakest. Even a well-managed domestic CM may be sourcing its input materials from overseas suppliers, many of them in tariff-affected geographies. The finished device is assembled in the U.S., but tariff exposure still exists.

This gap reflects the fundamental reality of how globally integrated medical device sourcing has become over the past two decades. The issue is that most OEMs have evaluated their tariff exposure only at the tier they can see.

What makes this particularly consequential for medical device manufacturing is the compounding effect of shared sub-tier dependencies. As the manufacturer of record for your device, your CM owns the regulatory accountability. But without sub-tier transparency, neither party has the visibility needed to get ahead of a disruption before it reaches the production schedule.

Learn how Remington Medical’s contract manufacturing services integrate in-house capabilities to reduce sub-tier dependency and give OEMs greater visibility into how their devices are actually made.

Our Contract Manufacturing Services

Why Medical Device OEMs Are Especially Vulnerable

The medical device supply chain carries a set of structural constraints that make sub-tier disruption far more damaging than in most other industries. A medical device OEM facing a component shortage may be looking at months of requalification work, regulatory documentation, and potential design changes before a substitute component can enter production.

That recovery time is a vulnerability, and it’s why medical supply chain disruption that originates at Tier 2 or Tier 3 can have an outsized downstream impact on device availability, launch timelines, and compliance standing.

Several factors compound this exposure specifically for OEMs in the medtech space:

Component qualification lock-in. Precision components used in medical devices are often qualified to specific material and dimensional tolerances. Switching to an alternative supplier can trigger a requalification process that involves testing, documentation, and in some cases, regulatory submission.
Regulatory change burden. Any material or component change that affects device performance, safety, or labeling may require design history file updates, risk assessments, and potentially 510(k) or PMA amendments. The regulatory cost of a sub-tier disruption can dwarf the procurement cost.
Concentration risk across shared suppliers. When multiple programs share the same upstream inputs, a single sub-tier event can affect multiple product lines at once, multiplying the operational impact.
Long development cycles that extend exposure windows. In many cases, medical device product development timelines run two to five years. A sourcing map that looks stable at program launch may look very different by the time a device reaches commercialization, especially in a volatile tariff environment.

Managing these risks effectively through product lifecycle management requires that sub-tier visibility be built into the manufacturing relationship from the start.

The Questions Your CM Should Be Able to Answer

The most direct way for an OEM to assess its sub-tier exposure is to ask its manufacturing partners the questions that most procurement conversations never reach. A capable medical device contract manufacturer should be able to speak clearly about where its key input materials and components come from, which suppliers are single-sourced versus dual-sourced, and how much of its upstream supply base is concentrated in tariff-affected geographies.

Beyond country-of-origin transparency, OEMs should be asking how their CM handles sub-tier disruption when it does occur. What is the qualification lead time for an alternative Tier 2 supplier? Does the CM maintain safety stock on critical components, and if so, at what levels? Has the CM developed an understanding of its own Tier 3 exposure, or does visibility stop at the direct vendor relationship?

These are the questions that separate a transactional manufacturing vendor from a strategic supply chain partner. An in-house manufacturing capability is one of the most structurally sound answers to these questions. It doesn’t eliminate sub-tier risk entirely, but it compresses the number of external dependencies that can introduce tariff exposure and disruption.

For OEMs serious about understanding their true medical device supply chain risk posture, the conversation has to go deeper than the CM’s front door.

Talk to a Team That Knows Its Supply Chain

Remington Medical has spent more than 30 years building manufacturing capabilities designed to reduce the dependencies that create sub-tier risk. If you’re evaluating your current exposure or looking for a partner with genuine sourcing transparency, we’re ready to have that conversation.

Reach out to our team to discuss your program and what a more resilient manufacturing relationship could look like.

Where Tariff Risk Lives in Your Medical Device Supply Chain

The Assumption That’s Leaving OEMs Exposed

Understanding the Supplier Tier Structure

Tier 1: Your Contract Manufacturer

Tier 2: Your CM’s Component Suppliers

Tier 3: Raw Materials and Specialty Inputs

Where the Tariff Risk Actually Lives

Why Medical Device OEMs Are Especially Vulnerable

The Questions Your CM Should Be Able to Answer

Talk to a Team That Knows Its Supply Chain

Share This Post

More Like This

How Offshore Sterilization and Lab Testing Can Delay Medical Device Launches

Dual-Sourcing Doesn’t Work When Both Sources Are Offshore: Rethink

Why Choosing a U.S.-Based Contract Manufacturer Matters in a High-Tariff Trade Environment

How Contract Manufacturing for Medical Devices Accelerates Innovation

Scaling Production: How to Transition From Prototype to Manufacturing Medical Devices

Medical Device Compliance After Brexit: CE vs. UKCA

How to Find the Right Manufacturing Partner: Key Questions to Ask Your Contract Manufacturer

How to Scale Medical Device Manufacturing Operations Efficiently

Balancing Quality With Cost in Medical Device Production

Get In Touch

Navigation

Recent Blogs